Pemvidutide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions not publicly disclosed. As a peptide with lipid modification, refrigerated storage (2-8 degrees C) is expected.
Protocol Quick-Reference
Obesity and MASH treatment
Dosing
Amount
1.2-2.4 mg
Frequency
Once weekly
Duration
48 weeks (Phase 2b)
Administration
Route
SCSchedule
Once weekly
Timing
No dose titration required; patients start directly on target dose unlike most GLP-1 agonists
Cycle
Duration
Ongoing (long-term use intended)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
Liver function tests (ALT, AST)
When: Baseline
Why: Baseline hepatic function for MASH monitoring
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Liver function tests and MRI-PDFF
When: 24 weeks
Why: Assess liver fat reduction and MASH improvement
Lipid panel
When: 48 weeks
Why: Monitor metabolic improvements
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority
- โNo dose titration required, simplifying treatment initiation
- โDual GLP-1/glucagon mechanism provides simultaneous weight loss and liver fat reduction
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| MASH Treatment (IMPACT Phase 2b) | 1.2 mg or 1.8 mg once weekly subcutaneous injection. No dose titration required. | Once weekly subcutaneous injection | 48 weeks (Phase 2b trial) | The 1.2 mg dose achieved 59.1% MASH resolution. The 1.8 mg dose achieved 54.7% liver fat reduction by MRI-PDFF at 48 weeks. |
| Weight Management (MOMENTUM Phase 2b) | 1.2 mg, 1.8 mg, or 2.4 mg once weekly subcutaneous injection. No dose titration required. | Once weekly subcutaneous injection | 48 weeks (Phase 2b trial) | The 2.4 mg dose achieved 15.6% total body weight loss at 48 weeks. 78.1% of weight loss was from fat mass. The 1.8 mg dose achieved approximately 11-12% weight loss. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Specific reconstitution instructions have not been publicly disclosed. Pemvidutide is administered as a once-weekly subcutaneous injection.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions not publicly disclosed. As a peptide with lipid modification, refrigerated storage (2-8 degrees C) is expected.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Pemvidutide is an investigational drug not approved by any regulatory authority. All dosing information is derived from clinical trials.
Phase 2b Trial Dosing#
A key advantage of pemvidutide is that it does not require dose titration. Patients start directly on their target dose, unlike most GLP-1 receptor agonists that require gradual dose escalation.
| Trial | Doses Studied | Duration | Primary Endpoint |
|---|---|---|---|
| IMPACT (MASH) | 1.2 mg, 1.8 mg weekly | 48 weeks | MASH resolution |
| MOMENTUM (Obesity) | 1.2 mg, 1.8 mg, 2.4 mg weekly | 48 weeks | Weight loss |
Weight Loss by Dose#
| Dose | Weight Loss at 48 Weeks | Fat Mass Contribution |
|---|---|---|
| 1.2 mg weekly | Moderate | Not reported separately |
| 1.8 mg weekly | 11-12% | Not reported separately |
| 2.4 mg weekly | 15.6% | 78.1% of total weight loss |
Administration#
Pemvidutide is administered as a once-weekly subcutaneous injection. The absence of dose titration simplifies treatment initiation and may improve adherence compared to agents requiring multi-week escalation schedules.
Dosing Context#
Pemvidutide belongs to the Metabolic category of research peptides. Dosing protocols for Pemvidutide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Pemvidutide:
MASH Treatment (IMPACT Phase 2b)#
Dose: 1.2 mg or 1.8 mg once weekly subcutaneous injection. No dose titration required.
Frequency: Once weekly subcutaneous injection
Duration: 48 weeks (Phase 2b trial)
The 1.2 mg dose achieved 59.1% MASH resolution. The 1.8 mg dose achieved 54.7% liver fat reduction by MRI-PDFF at 48 weeks.
Weight Management (MOMENTUM Phase 2b)#
Dose: 1.2 mg, 1.8 mg, or 2.4 mg once weekly subcutaneous injection. No dose titration required.
Frequency: Once weekly subcutaneous injection
Duration: 48 weeks (Phase 2b trial)
The 2.4 mg dose achieved 15.6% total body weight loss at 48 weeks. 78.1% of weight loss was from fat mass. The 1.8 mg dose achieved approximately 11-12% weight loss.
Reconstitution and Preparation#
Specific reconstitution instructions have not been publicly disclosed. Pemvidutide is administered as a once-weekly subcutaneous injection.
Injection Sites#
Recommended injection sites for Pemvidutide include:
- Abdomen
- Thigh
- Upper arm
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions not publicly disclosed. As a peptide with lipid modification, refrigerated storage (2-8 degrees C) is expected.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Pemvidutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.